November 2013 Safety Labeling Changes includes 27 products with revisions to prescribing information

The MedWatch November 2013 Safety Labeling Changes posting includes 27 products with safety labeling changes to the following sections: BOXED WARNINGS, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS and PATIENT PACKAGE INSERT.

This content was written and submitted by the supplier. It has only been modified to comply with this publication’s space and style.

The "Summary Page" provides a listing of product names and safety labeling sections revised:

http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm377096.htm

The following drugs had modifications to the CONTRAINDICATIONS, WARNINGS and PRECAUTIONS sections:

Prevpac (Lansoprazole 30 mg delayed-release, Amoxicillin 500 mg capsules and Clarithromycin 500 mg tablets)
Zestoretic (Lisinopril/Hydrochlorothiazide)
Zestril (Lisinopril)
Amturnide (Aliskiren, Amlodipine and Hydrochlorothiazide)
Aralen (Chloroquine Phosphate) 
Jakafi (Ruxolitibib)
Lysodren (Mitotane)
Nexavar (Sorafenib)
Noxafil (Posaconazole)   
Onfi (Clobazam)     
Remicade (Infliximab)
Revlimid (Lenalidomide)
Simponi (Golimumab)
Tekamlo (Aliskiren and Amlodipine)
Tekturna (Aliskiren)
Tekturna HCT (Aliskiren and Hydrochlorothiazide)
Xalkori (Crizotinib)

Sustainable Healthcare Packaging Solutions That Work
Industry leaders share proven strategies for reducing packaging emissions by up to 70% while meeting safety and regulatory requirements.
Read More
Sustainable Healthcare Packaging Solutions That Work
List: Digitalization Companies From PACK EXPO
Looking for CPG-focused digital transformation solutions? Download our editor-curated list from PACK EXPO featuring top companies offering warehouse management, ERP, digital twin, and MES software with supply chain visibility and analytics capabilities—all tailored specifically for CPG operations.
Download Now
List: Digitalization Companies From PACK EXPO